The SA Journal Diabetes & Vascular Disease Vol 8 No 1 (March 2011) - page 5

References: 1.
Zander M,
et al.
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and ß-cell function
in type 2 diabetes: a parallel-group study.
Lancet
. 2002;359:824-830.
2.
Toft-Nielsen M-B,
et al.
Determinants of the Impaired Secretion
of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients.
J Clin Endocrinol Metab
. 2001;86(8):3717-3723.
3.
Kjems LL,
et al.
The Influence of GLP-1
on Glucose-Stimulated Insulin Secretion. Effects on ß-Cell Sensitivity in Type 2 and Nondiabetic Subjects.
Diabetes
. 2003;52:380-386.
Novo Nordisk (Pty) Ltd. Reg. No.: 1959/000833/07. PO Box 783155, Sandton, 2146. Tel: (011) 202 0500 Fax: (011) 807 7989
NN/DUO/4244/09/10/VER1
Diabetes |
A whole new perspective
Are you
looking at
every part
of diabetes?
You might be missing GLP-1.
It’s a
natural hormone that helps regulate glucose
metabolism. It also slows gastric emptying,
promotes satiety, and plays a significant role
in beta-cell function.
1
Its multiple actions
throughout the body are critical in diabetes.
Unfortunately, your patients might be
missing GLP-1, too.
Many people with
type 2 diabetes may have impaired GLP-1
secretion and impaired beta-cell response
to GLP-1.
2,3
This could contribute to the
pathogenesis of the disease.
1
Looking at the whole problem is the most
important part of understanding it. That’s why
Novo Nordisk is dedicated to ongoing research
and development in the management of
diabetes.
1,2,3,4 6,7,8,9,10,11,12,13,14,15,...52
Powered by FlippingBook